|Bid||73.74 x 200|
|Ask||73.83 x 1300|
|Day's Range||73.62 - 75.29|
|52 Week Range||63.76 - 84.15|
|PE Ratio (TTM)||7.79|
|Dividend & Yield||2.08 (2.82%)|
|1y Target Est||N/A|
Healthcare giant Gilead Sciences, Inc. (NASDAQ:GILD) is gearing up for another quarterly report after the closing bell on Wednesday. This time, the report will cover results from the second quarter of fiscal 2017.
We have three pharma giants that are set to report second-quarter results on Jul 26. Let's see how things are shaping up for this quarter.
Gilead Sciences (GILD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP.